CClinicalTrials.gg
Sign In
CompletedNCT02758392Updated Jan 23, 2017

A Study to Evaluate Safety and Tolerability of JNJ-61178104 in Healthy Participants

A Phase 1 interventional study of JNJ-61178104 Intravenous and JNJ-61178104 Subcutaneous in Healthy, sponsored by Janssen Research & Development, LLC. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-01-23.

Sponsored by Janssen Research & Development, LLC · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and immunogenicity of JNJ-61178104 following a single ascending Intravenous (IV) dose administration and a single Subcutaneous (SC) dose administration in healthy participants.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, single ascending dose, single site, interventional study. There will be 5 single ascending dose (SAD) IV cohorts and 1 SC cohort. Nine participants will be enrolled into each of 5 IV cohorts and 1 SC cohort and participants will be randomized at a ratio of 2:1 to receive JNJ-61178104 or placebo. The total duration of participants participation will be approximately 21 weeks including a Screening Visit up to 4 weeks prior to study drug administration. Participants will have an inpatient period consisting of 6 days/5 nights and will return to the study-site at Weeks 2, 3, 4, 5, 7, 9, 13, and 17. Participants will be evaluated for safety throughout the study.

02

Conditions studied

  • Healthy

Keywords

  • Healthy
  • JNJ-61178104
  • Placebo
  • Safety
03

In context

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 912 studies on the registry; 76 are open to participants now.

Of its 278 completed or terminated interventional studies of FDA-regulated products, 131 (47%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Participant must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study
  • Participant must have a body weight in the range of 50 Kilogram (kg) to 100 kg, inclusive, and have a body mass index of 19 Kilogram per meter square (kg/m\^2) to 30 kg/m2, inclusive
  • Participant must be healthy on the basis of clinical laboratory tests performed at Screening and Day-1. If the results of the serum chemistry panel including liver enzymes, hematology panel, or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the participant's medical record with documented review confirmation by the investigator
  • Before randomization, a woman must not be of childbearing potential: a) Postmenopausal {greater than (>) 45 years of age with amenorrhea for at least 12 months or any age with amenorrhea for at least 6 months and a serum follicle stimulating hormone (FSH) level >40 International Units Per Litre (IU/L) at Screening}; or b) Permanently sterilized (example, bilateral tubal occlusion, hysterectomy, bilateral salpingectomy, oophorectomy); or c) Otherwise be incapable of pregnancy
  • Be considered eligible according to the following tuberculosis (TB) Screening criteria: a) Have no history of latent or active TB prior to Screening; b) Have no signs or symptoms suggestive of active TB upon medical history and/or physical examination; c) Have had no recent close contact with a person with active TB; d) Have a negative T-Spot TB test result at Screening

Exclusion criteria

Exclusion Criteria:

  • Participant currently has or has a history of any clinically significant medical illness or medical disorders the investigator considers should exclude the participant, including (but not limited to), neuromuscular, hematological disease, immune deficiency state, cardiac, vascular, metabolic, endocrine, rheumatologic, respiratory disease, hepatic or gastrointestinal disease, neurological or psychiatric disease, ophthalmological disorders, neoplastic disease, renal or urinary tract diseases, or dermatological disease
  • Participant has a QT corrected according to Fridericia's formula (QTcF) interval >450 msec, has a complete left or right bundle branch block, or has a history or current evidence of additional risk factors for torsades de pointes (example, heart failure, hypokalemia, family history of Long QT Syndrome) at Screening and at Day -1
  • Participant has had major surgery, (example, requiring general anesthesia) within 4 months before Screening, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study or within 17 weeks after the last dose of study drug administration
  • Participant plans to undergo non-major elective surgery within 4 weeks prior to study drug administration through the end of the study
  • Participant has a known or suspected intolerance or hypersensitivity to any biologic medication or known allergies or clinically significant reactions to murine, chimeric, or human proteins, monoclonal antibodies or antibody fragments, or to any components of the formulation of JNJ-61178104 and its excipients used in this study
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Dose 1: JNJ-61178104 OR Placebo IV

    Participants will receive either JNJ-61178104 0.1 milligram/kilogram (mg/kg) or Placebo Intravenously (IV) on Day 1.

    Drug: JNJ-61178104 Intravenous · Drug: Placebo

  • Experimental
    Dose 2: JNJ-61178104 OR Placebo IV

    Participants will receive either JNJ-61178104 0.3 mg/kg or Placebo IV on Day 1.

    Drug: JNJ-61178104 Intravenous · Drug: Placebo

  • Experimental
    Dose 3: JNJ-61178104 OR Placebo IV

    Participants will receive either JNJ-61178104 1 mg/kg or Placebo IV on Day 1.

    Drug: JNJ-61178104 Intravenous · Drug: Placebo

  • Experimental
    Dose 4: JNJ-61178104 OR Placebo IV

    Participants will receive either JNJ-61178104 3 mg/kg or Placebo IV on Day 1.

    Drug: JNJ-61178104 Intravenous · Drug: Placebo

  • Experimental
    Dose 5: JNJ-61178104 OR Placebo IV

    Participants will receive either JNJ-61178104 10 mg/kg or Placebo IV on Day 1.

    Drug: JNJ-61178104 Intravenous · Drug: Placebo

  • Experimental
    Dose 6: JNJ-61178104 OR Placebo SC

    Participants will receive either JNJ-61178104 1 mg/kg or Placebo Subcutaneously (SC) on Day 1.

    Drug: JNJ-61178104 Subcutaneous · Drug: Placebo

Interventions

  • DrugJNJ-61178104 Intravenous

    Participants will receive JNJ-61178104 Intravenously on Day 1.

  • DrugJNJ-61178104 Subcutaneous

    Participants will receive JNJ-61178104 Subcutaneously on Day 1.

  • DrugPlacebo

    Participants will receive placebo on Day 1.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events Following Study Drug Administration as a Measure of Safety and Tolerability

    Time frame: Day 113

Secondary outcomes

  1. Serum Concentration of JNJ-61178104

    Time frame: Up to Day 113

  2. JNJ-61178104 Antibodies Concentration

    Time frame: Up to Day 113

  3. Cytokine Concentrations

    Time frame: Predose, Up to Day 113

  4. Maximum Observed Serum Concentration (Cmax) Following Intravenous (IV) and Subcutaneous (SC) JNJ-61178104 Administration

    Time frame: Up to Day 113

  5. Area Under the Serum Concentration-Time Curve From Time Zero to Time 't' (AUC[0-t]) Following Intravenous (IV) and Subcutaneous (SC) JNJ-61178104 Administration

    Time frame: Up to Day 113

  6. Area Under the Serum Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) Following Intravenous (IV) and Subcutaneous (SC) JNJ-61178104 Administration

    Time frame: Up to Day 113

  7. Serum Half-Life (t1/2) Following Intravenous (IV) and Subcutaneous (SC) JNJ-61178104 Administration

    Time frame: Up to Day 113

  8. Time to Reach Maximum Observed Serum Concentration (Tmax) Following Subcutaneous (SC) JNJ-61178104 Administration

    Time frame: Up to Day 113

  9. Systemic Clearance (CL) Following Intravenous (IV) JNJ-61178104 Administration

    Time frame: Up to Day 113

  10. Apparent Clearance (CL/F) Following Subcutaneous (SC) JNJ-61178104 Administration

    Time frame: Up to Day 113

  11. Volume of Distribution (Vz) Following Intravenous (IV) JNJ-61178104 Administration

    Time frame: Up to Day 113

  12. Apparent Volume of Distribution (Vz/F) Following Subcutaneous (SC) JNJ-61178104 Administration

    Time frame: Up to Day 113

  13. Absolute Bioavailability (F[abs]) Following Subcutaneous (SC) JNJ-61178104 Administration

    The F is the percentage of the subcutaneously administered dose that is systemically available relative to an intravenous (IV) administration. It is calculated as (AUC \[0-infinity\] for 1 mg/kg SC JNJ-61178104)/(AUC \[0-infinity\] for 1 mg/kg IV JNJ-61178104 )\*100, where the AUC (0-infinity) is area under the concentration-time curve from time zero to extrapolated infinite time.

    Time frame: Up to Day 113

07

Study locations

1 site
  • Merksem, Belgium
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02758392
Lead sponsor
Janssen Research & Development, LLC
Responsible party
Sponsor
First posted
May 2, 2016
Start date
Apr 2016
Primary completion
Jan 2017
Completion
Jan 2017
Last update
Jan 23, 2017

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Janssen Research & Development, LLC

Start the discussion